Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. Cyt 387
2. Cyt-387
3. Cyt387
4. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
1. Cyt387
2. 1056634-68-4
3. Cyt-387
4. Cyt 387
5. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide
6. Cyt 11387
7. N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide
8. Gs-0387
9. Momelotinib (cyt387)
10. Cyt-11387
11. N-(cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide
12. N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
13. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide
14. 6o01gms00p
15. Chembl1078178
16. Cyt-0387
17. Cyt11387
18. Mfcd16038899
19. Lm-1149
20. N-(cyanomethyl)-4-(2-((4-(morpholin-4-yl)phenyl)amino)pyrimidin-4-yl)benzamide
21. N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide
22. Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-
23. Momelotinib [usan]
24. Momelotinib [usan:inn]
25. Momelotinibum
26. Unii-6o01gms00p
27. Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-
28. C87
29. Momelotinib [inn]
30. Momelotinib (usan/inn)
31. Momelotinib [who-dd]
32. Mls006011154
33. Gtpl7791
34. Schembl2237234
35. Chebi:91407
36. Ex-a260
37. Dtxsid801026049
38. Hms3244k19
39. Hms3244k20
40. Hms3244l19
41. Hms3295i01
42. Hms3655d12
43. Hms3744c15
44. Bcp02328
45. Cyt387, Cyt11387
46. Cyt387,cyt 11387
47. Momelotinib (cyt387,cyt-387)
48. Bdbm50311017
49. Nsc767598
50. Nsc800800
51. S2219
52. Zinc43199890
53. Akos015904624
54. N-(cyanomethyl)-4-[2-[(4-morpholinophenyl)amino]-4-pyrimidinyl]benzamide
55. Bcp9000570
56. Ccg-264946
57. Cs-0053
58. Db11763
59. Nsc-767598
60. Nsc-800800
61. Sb14602
62. Ncgc00244257-01
63. Ncgc00244257-08
64. Ac-23162
65. As-19389
66. Hy-10961
67. Smr004702928
68. Sy060668
69. Ft-0755949
70. Sw219679-1
71. D10315
72. A857769
73. Q252602
74. J-001468
75. J-523159
76. Brd-k87737963-001-01-1
77. N-(cyanomethyl)-4-(2-(4-morpholinoanilino)pyrimidin-4-yl)benzamide
78. N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide
79. N-(cyanomethyl)-4-[2-[4-(4-morpholinyl)anilino]-4-pyrimidinyl]benzamide
80. N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide
81. Benzamide,n-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-
82. N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide;cyt387
83. Cyt 11387, Cyt-387, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]benzamide
Molecular Weight | 414.5 g/mol |
---|---|
Molecular Formula | C23H22N6O2 |
XLogP3 | 2.6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 6 |
Exact Mass | 414.18042397 g/mol |
Monoisotopic Mass | 414.18042397 g/mol |
Topological Polar Surface Area | 103 Ų |
Heavy Atom Count | 31 |
Formal Charge | 0 |
Complexity | 615 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of myelofibrosis
Treatment of post-polycythaemia vera myelofibrosis, Treatment of polycythaemia vera, Treatment of post-essential thrombocythaemia myelofibrosis, Treatment of essential thrombocythaemia, Treatment of acute lymphoblastic leukaemia
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Global Sales Information
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 36
2022 Revenue in Millions : 0
Growth (%) : New Launch
ABOUT THIS PAGE
A Momelotinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Momelotinib, including repackagers and relabelers. The FDA regulates Momelotinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Momelotinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Momelotinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Momelotinib supplier is an individual or a company that provides Momelotinib active pharmaceutical ingredient (API) or Momelotinib finished formulations upon request. The Momelotinib suppliers may include Momelotinib API manufacturers, exporters, distributors and traders.
click here to find a list of Momelotinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Momelotinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Momelotinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Momelotinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Momelotinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Momelotinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Momelotinib suppliers with NDC on PharmaCompass.
Momelotinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Momelotinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Momelotinib GMP manufacturer or Momelotinib GMP API supplier for your needs.
A Momelotinib CoA (Certificate of Analysis) is a formal document that attests to Momelotinib's compliance with Momelotinib specifications and serves as a tool for batch-level quality control.
Momelotinib CoA mostly includes findings from lab analyses of a specific batch. For each Momelotinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Momelotinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Momelotinib EP), Momelotinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Momelotinib USP).
LOOKING FOR A SUPPLIER?